Trial · NCT04152200
Results by group57
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 57
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Quality of Life As Assessed by Kidney Disease and Quality of Life (KDQOL) Scores From Baseline to Month 6 in Patients ≥18 Years of Age at Time of Informed Consent | Cohort B: Lumasiran | Burden of Kidney Disease | -4.69 | Standard Deviation 16.44 | score on a scale |
| Maximum Plasma Concentration (Cmax) of Lumasiran | Cohort A: Lumasiran | Day 1 | 1019.9 | Geometric Coefficient of Variation 61.6 | ng/mL |
| Maximum Plasma Concentration (Cmax) of Lumasiran | Cohort B: Lumasiran | Day 1 | 1820.5 | Geometric Coefficient of Variation 113.2 | ng/mL |
| Maximum Plasma Concentration (Cmax) of Lumasiran | All Lumasiran | Day 1 | 1542.8 | Geometric Coefficient of Variation 103.7 | ng/mL |
| Maximum Plasma Concentration (Cmax) of Lumasiran | Cohort A: Lumasiran | Month 6 | 1038.2 | Geometric Coefficient of Variation 36.9 | ng/mL |
| Maximum Plasma Concentration (Cmax) of Lumasiran | Cohort B: Lumasiran | Month 6 | 1289.3 | Geometric Coefficient of Variation 106.0 | ng/mL |
| Maximum Plasma Concentration (Cmax) of Lumasiran | All Lumasiran | Month 6 | 1211.9 | Geometric Coefficient of Variation 87.6 | ng/mL |
| Time to Maximum Plasma Concentration (Tmax) of Lumasiran | Cohort A: Lumasiran | Day 1 | 3.8083 | Full Range 1.767 to 11.533 | hours |
| Time to Maximum Plasma Concentration (Tmax) of Lumasiran | Cohort B: Lumasiran | Day 1 | 4.0000 | Full Range 1.717 to 12.000 | hours |
| Time to Maximum Plasma Concentration (Tmax) of Lumasiran | All Lumasiran | Day 1 | 4.0000 | Full Range 1.717 to 12.000 | hours |
| Time to Maximum Plasma Concentration (Tmax) of Lumasiran | Cohort A: Lumasiran | Month 6 | 3.9083 | Full Range 1.983 to 7.617 | hours |
| Time to Maximum Plasma Concentration (Tmax) of Lumasiran | Cohort B: Lumasiran | Month 6 | 4.0167 | Full Range 1.967 to 12.000 | hours |
| Time to Maximum Plasma Concentration (Tmax) of Lumasiran | All Lumasiran | Month 6 | 4.0000 | Full Range 1.967 to 12.000 | hours |
| Elimination Half-life (t½β) of Lumasiran | Cohort A: Lumasiran | Day 1 | 9.0246 | Full Range 3.364 to 10.593 | hours |
| Elimination Half-life (t½β) of Lumasiran | Cohort B: Lumasiran | Day 1 | 3.6670 | Full Range 1.127 to 7.793 | hours |
| Elimination Half-life (t½β) of Lumasiran | All Lumasiran | Day 1 | 3.8302 | Full Range 1.127 to 10.593 | hours |
| Elimination Half-life (t½β) of Lumasiran | Cohort A: Lumasiran | Month 6 | 8.1069 | Full Range 2.420 to 10.796 | hours |
| Elimination Half-life (t½β) of Lumasiran | Cohort B: Lumasiran | Month 6 | 4.5131 | Full Range 1.388 to 7.354 | hours |
| Elimination Half-life (t½β) of Lumasiran | All Lumasiran | Month 6 | 5.7484 | Full Range 1.388 to 10.796 | hours |
| Area Under the Concentration-time Curve From 0 to 24 Hours [AUC(0-24)] for Lumasiran | Cohort A: Lumasiran | Day 1 | 13156.8031 | Geometric Coefficient of Variation 64.6 | h*ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04152200/results?page=2